Genetic Technologies Profit Margin 2010-2022 | GENE

Current and historical gross margin, operating margin and net profit margin for Genetic Technologies (GENE) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Genetic Technologies net profit margin as of June 30, 2022 is 0%.
Genetic Technologies Annual Profit Margins
Genetic Technologies Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.025B $0.005B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.441B 9.68
GSK (GSK) United Kingdom $74.044B 9.78
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.308B 21.01
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.617B 0.00
Arcus Biosciences (RCUS) United States $1.545B 23.20
Biohaven (BHVN) United States $1.265B 0.00
Emergent Biosolutions (EBS) United States $0.703B 5.53
ADC Therapeutics SA (ADCT) Switzerland $0.348B 0.00
Enzo Biochem (ENZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.066B 0.00
Gelesis Holdings (GLS) United States $0.025B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00